Investing

Today's Market Winners and Losers

Stocks are down midday Monday, with the Dow Jones Industrial Average down 0.30%, the Nasdaq down 0.22% and the S&P 500 down 0.15%. Today’s big winners are two pharmaceutical companies, with one getting bought out by private equity and another showing a successful trial of one of its drugs. Meanwhile, a stock sale sends a medical technology company lower while energy woes continue to hit the coal sector, sending one company on the loser list.

Here are Monday’s market winners and losers.

Biggest Winners

Shares of Par Pharmaceuticals (NYSE: PRX) are up 37.21% to $50.16 on trading volume of 3.9 million shares. Private equity firm TPG announced Monday it would purchase Par for $1.9 billion, or $50 a share. Before Monday, the 52-week high was $42.80.

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are up 26.12% to $15.79 on trading volume of 1.9 million shares. The company announced positive results from its Phase I trial of ALN-TTR02 , which helps treat a form of amylodosis. Before Monday, the 52-week high was $13.75.

Biggest Losers

Shares of IsoRay (ASE: ISR) are down 21.09% to $1.16 on trading volume of 2.7 million shares. The medical technology company announced it is selling about $3.5 million of its common stock. The 52-week low of the stock is $0.38.

Shares of Alpha Natural Resources (NYSE: ANR) are down 10.68% to $6.82 on trading volume of 7.1 million shares. Energy stocks are taking a big hit Monday, and Alpha Natural was cut to “underperform” by BMO Capital Markets, according to MarketWatch. Before Monday, the 52-week low was $7.17.

Samuel Weigley

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.